Suchergebnisse
Suchergebnisse:
Sir Gregory Paul Winter CBE FRS FMedSci (born 14 April 1951) is a Nobel Prize-winning English molecular biologist best known for his work on the therapeutic use of monoclonal antibodies. His research career has been based almost entirely at the MRC Laboratory of Molecular Biology and the MRC Centre for Protein Engineering , in ...
Sir Gregory „Greg“ Paul Winter, CBE (* 14. April 1951 in Leicester ), ist ein britischer Molekularbiologe, Nobelpreisträger und Pionier der Monoklonalen Antikörper und des Phagen-Displays . Inhaltsverzeichnis. 1 Karriere. 2 Auszeichnungen und Mitgliedschaften. 3 Schriften (Auswahl) 4 Literatur. 5 Weblinks. 6 Einzelnachweise. Karriere.
3. Okt. 2018 · Greg Winter, a genetic engineer and Master of Trinity College, is recognised for his pioneering work in using phage display for the directed evolution of antibodies. He founded three Cambridge biotech companies based on his inventions and developed new therapies for rheumatoid arthritis, psoriasis and cancer.
Sir Gregory P. Winter. The Nobel Prize in Chemistry 2018. Born: 14 April 1951, Leicester, United Kingdom. Affiliation at the time of the award: MRC Laboratory of Molecular Biology, Cambridge, United Kingdom. Prize motivation: “for the phage display of peptides and antibodies” Prize share: 1/4. Life.
10. Mai 2024 · Gregory P. Winter (born April 14, 1951, Leicester, England) is a British biochemist known for his development of the first humanized antibodies, his research on the directed evolution of antibodies, and his application of phage display technology for the development of fully human therapeutic antibodies.
- Kara Rogers
I was also Deputy Director of the MRC Centre for Protein Engineering (1990–2010), and held Fellowships at Trinity College, Cambridge (1976–1980; 1990–2012; 2019–). I was appointed Master of Trinity from 2012–2019. My research developed from my interests in the chemistry and structure of proteins and nucleic acids.
Greg Winter. The Cambridge Phenomenon. Winter established three spin-out companies to develop the phage display technologies. Among them was Cambridge Antibody Technology (CAT), which he founded with Dr David Chiswell and Dr John McCafferty in 1989.
